SB239 Alabama 2023 Session

Updated Jan 14, 2026

Senate Bill

Enacted

Current Status

Regular Session 2023

Session

Sponsor

Summary

Primary Sponsor: Larry Stutts Senator
Republican
Session: Regular Session 2023
Title: Relating to Opioid Addiction Treatment; to repeal the Medication Assisted Treatment of Opioid Use Act of 2019, codified as Sections 20-2-300 through 20-2-302, Code of Alabama 1975, that provide for adoption of rules governing use of buprenorphine in the treatment of opioid addiction and a standing working group to assist in drafting the rules.
Description: The Medication Assisted Treatment of Opioid Use Act of 2019 ("MAT Act"), requires the Alabama Board of Medical Examiners to adopt rules governing the prescribing and use of medications containing buprenorphine to treat opioid addiction in the nonresidential setting. The rules authorized by The MAT Act relate to dosage, screening, therapy, and record-keeping related to treatment with buprenorphine.
A standard working group with members who specialize in addiction is also provided to assist in adoption of the rules.
Since enactment, changes in federal law and policy governing medication-assisted treatment of opioid addiction have created conflicts with the provisions of the MAT Act.
This bill would repeal the MAT Act.
Subjects: Medication Assisted Treatment of Opioid Use Act, repealed